Impact of Hematopoietic Cell Transplantation on Myocardial Fibrosis in Young Patients with Sickle Cell Disease

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2024 May 1

PMID 38691679

Authors

Akshay Sharma

Subodh Selukar

Yu Bi

Anthony Merlocco

Cara E Morin

Chris Goode

Parul Rai

Jeffrey A Towbin

Jane S Hankins

Stephen Gottschalk

Brandon Triplett

Jason N Johnson

Affiliations

Soon will be listed here.

Abstract

Serial cardiovascular magnetic resonance evaluation of children and young adults with SCD who underwent hematopoietic cell transplantation showed mean ECV, representing diffuse myocardial fibrosis, decreased 3.4% from baseline to 12 months posttransplantation. This trial was registered at www.clinicaltrials.gov as #NCT04362293.

Citing Articles

How I treat sickle cell disease with gene therapy.

Sharma A Blood. 2024; 144(26):2693-2705.

PMID: 39356871 PMC: 11830977. DOI: 10.1182/blood.2024024519.

References

Karamitsos T, Arvanitaki A, Karvounis H, Neubauer S, Ferreira V . Myocardial Tissue Characterization and Fibrosis by Imaging. JACC Cardiovasc Imaging. 2019; 13(5):1221-1234. DOI: 10.1016/j.jcmg.2019.06.030. View

Bakeer N, James J, Roy S, Wansapura J, Shanmukhappa S, Lorenz J . Sickle cell anemia mice develop a unique cardiomyopathy with restrictive physiology. Proc Natl Acad Sci U S A. 2016; 113(35):E5182-91. PMC: 5024607. DOI: 10.1073/pnas.1600311113. View

Kellman P, Wilson J, Xue H, Ugander M, Arai A . Extracellular volume fraction mapping in the myocardium, part 1: evaluation of an automated method. J Cardiovasc Magn Reson. 2012; 14:63. PMC: 3441905. DOI: 10.1186/1532-429X-14-63. View

Thein S, Sachdev V . Diffuse myocardial fibrosis as an SCD biomarker. Blood. 2022; 140(11):1191-1192. PMC: 9479032. DOI: 10.1182/blood.2022017725. View

Haaf P, Garg P, Messroghli D, Broadbent D, Greenwood J, Plein S . Cardiac T1 Mapping and Extracellular Volume (ECV) in clinical practice: a comprehensive review. J Cardiovasc Magn Reson. 2016; 18(1):89. PMC: 5129251. DOI: 10.1186/s12968-016-0308-4. View

Meloni A, Pistoia L, Quota A, Messina G, Ricchi P, Bagnato S . Prognostic value of multiparametric cardiac magnetic resonance in sickle cell patients. Ann Hematol. 2022; 102(2):261-270. DOI: 10.1007/s00277-022-05057-6. View

Gladwin M . Cardiovascular complications and risk of death in sickle-cell disease. Lancet. 2016; 387(10037):2565-74. DOI: 10.1016/S0140-6736(16)00647-4. View

Dallas M, Triplett B, Shook D, Hartford C, Srinivasan A, Laver J . Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2013; 19(5):820-30. PMC: 4712646. DOI: 10.1016/j.bbmt.2013.02.010. View

Morita N, Mandel W, Kobayashi Y, Karagueuzian H . Cardiac fibrosis as a determinant of ventricular tachyarrhythmias. J Arrhythm. 2015; 30(6):389-394. PMC: 4308294. DOI: 10.1016/j.joa.2013.12.008. View

10.

dHumieres T, Saba J, Savale L, Dupuy M, Boyer L, Guillet H . Determinants of ventricular arrhythmias in sickle cell anemia: toward better prevention of sudden cardiac death. Blood. 2023; 142(5):409-420. DOI: 10.1182/blood.2022019571. View

11.

Paszty C, Brion C, Manci E, Witkowska H, Stevens M, Mohandas N . Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science. 1997; 278(5339):876-8. DOI: 10.1126/science.278.5339.876. View

12.

Diao K, Yang Z, Xu H, Liu X, Zhang Q, Shi K . Histologic validation of myocardial fibrosis measured by T1 mapping: a systematic review and meta-analysis. J Cardiovasc Magn Reson. 2016; 18(1):92. PMC: 5154013. DOI: 10.1186/s12968-016-0313-7. View

13.

Sibley C, Noureldin R, Gai N, Nacif M, Liu S, Turkbey E . T1 Mapping in cardiomyopathy at cardiac MR: comparison with endomyocardial biopsy. Radiology. 2012; 265(3):724-32. PMC: 3504318. DOI: 10.1148/radiol.12112721. View

14.

Niss O, Detterich J, Wood J, Coates T, Malik P, Taylor M . Early initiation of disease-modifying therapy can impede or prevent diffuse myocardial fibrosis in sickle cell anemia. Blood. 2022; 140(11):1322-1324. PMC: 9479038. DOI: 10.1182/blood.2021015303. View

15.

Galan-Arriola C, Lobo M, Vilchez-Tschischke J, Lopez G, de Molina-Iracheta A, Perez-Martinez C . Serial Magnetic Resonance Imaging to Identify Early Stages of Anthracycline-Induced Cardiotoxicity. J Am Coll Cardiol. 2019; 73(7):779-791. DOI: 10.1016/j.jacc.2018.11.046. View

16.

Kwiecinski J, Lennen R, Gray G, Borthwick G, Boswell L, Baker A . Progression and regression of left ventricular hypertrophy and myocardial fibrosis in a mouse model of hypertension and concomitant cardiomyopathy. J Cardiovasc Magn Reson. 2020; 22(1):57. PMC: 7409657. DOI: 10.1186/s12968-020-00655-7. View

17.

Melendez G, Jordan J, DAgostino Jr R, Vasu S, Hamilton C, Hundley W . Progressive 3-Month Increase in LV Myocardial ECV After Anthracycline-Based Chemotherapy. JACC Cardiovasc Imaging. 2016; 10(6):708-709. PMC: 7890530. DOI: 10.1016/j.jcmg.2016.06.006. View

18.

Lopez B, Ravassa S, Moreno M, San Jose G, Beaumont J, Gonzalez A . Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches. Nat Rev Cardiol. 2021; 18(7):479-498. DOI: 10.1038/s41569-020-00504-1. View

19.

Alsaied T, Niss O, Tretter J, Powell A, Chin C, Fleck R . Left atrial dysfunction in sickle cell anemia is associated with diffuse myocardial fibrosis, increased right ventricular pressure and reduced exercise capacity. Sci Rep. 2020; 10(1):1767. PMC: 7000788. DOI: 10.1038/s41598-020-58662-8. View

20.

Nagueh S, Smiseth O, Appleton C, Byrd 3rd B, Dokainish H, Edvardsen T . Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2016; 17(12):1321-1360. DOI: 10.1093/ehjci/jew082. View